← Back to Search

MCL1 Inhibitor

PRT1419 for Non-Hodgkin's Lymphoma

Phase 1
Waitlist Available
Research Sponsored by Prelude Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through approximately 2 years
Awards & highlights

Study Summary

This trial is testing a new cancer drug to see what the best dose is and if it has any side effects.

Eligible Conditions
  • Non-Hodgkin's Lymphoma
  • Myelodysplastic Syndrome
  • Multiple Myeloma
  • Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through approximately 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through approximately 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To describe dose limiting toxicities (DLT) of PRT1419
To determine the maximally tolerated dose (MTD) and/or optimal biological dose (OBD)
To determine the recommended phase 2 dose (RP2D) and schedule of PRT1419
Secondary outcome measures
To describe any anti-tumor activity of PRT1419
To describe the adverse event profile and tolerability of PRT1419
To describe the pharmacokinetic profile of PRT1419

Trial Design

1Treatment groups
Experimental Treatment
Group I: PRT1419Experimental Treatment1 Intervention
PRT1419 will be administered orally
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PRT1419
2020
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

Prelude TherapeuticsLead Sponsor
8 Previous Clinical Trials
639 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
2020. "A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04543305.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top